[HTML][HTML] A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation
J Pidala, J Kim, H Jim, MA Kharfan-Dabaja… - …, 2012 - ncbi.nlm.nih.gov
Haematologica, 2012•ncbi.nlm.nih.gov
Background There is evidence suggesting that sirolimus, in combination with tacrolimus, is
active in the prevention of graft-versus-host disease. Sirolimus-based immune suppression
may suppress alloreactive T cells, while sparing the survival and function of regulatory T
cells.
active in the prevention of graft-versus-host disease. Sirolimus-based immune suppression
may suppress alloreactive T cells, while sparing the survival and function of regulatory T
cells.
Abstract
Background
There is evidence suggesting that sirolimus, in combination with tacrolimus, is active in the prevention of graft-versus-host disease. Sirolimus-based immune suppression may suppress alloreactive T cells, while sparing the survival and function of regulatory T cells.
ncbi.nlm.nih.gov